Skip to main content

Advertisement

SpringerLink
Log in

Algorithmen zur Systemtherapie bei Prostata‑, Urothel- und Nierenzellkarzinom

Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die Systemtherapie in der Uroonkologie ist aktuell einem starken Wandel unterworfen. In der Vergangenheit zeigten die medikamentösen Therapien nur bei metastasierten Hodentumoren gute Behandlungsergebnisse. Neue Entwicklungen deuten darauf hin, dass durch ein verbessertes Verständnis der Tumorbiologie zielgerichtete Therapiestrategien auch bei Metastasierung der Tumorentitäten Prostata‑, Urothel- und Nierenzellkarzinom bereits aktuell und in der Zukunft die Behandlung dieser Patienten deutlich verbessern wird. In dem folgenden Beitrag möchten wir die praxisrelevanten Neuerungen zur Systemtherapie in den Leitlinien zu den Themen Prostatakarzinom, Urothelkarzinom der Harnblase und Nierenzellkarzinom zusammenfassen.

Abstract

Systemic therapy in uro-oncology is currently undergoing major changes. In the past, drug therapies only showed good treatment results in metastasized testicular tumors. New developments indicate that an improved understanding of tumor biology will lead to targeted treatment strategies for metastatic prostate, urothelial and renal cell carcinoma. In the following article, we summarize the practice-relevant innovations in systemic therapy in the guidelines on prostate cancer, transitional cell carcinoma of the bladder and renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Nair B, Wilt T, MacDonald R, Rutks I (2002) Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003506

    Article  PubMed  Google Scholar 

  2. Iversen P et al (2006) Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group‑6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 40:441–452

    Article  CAS  Google Scholar 

  3. Studer UE et al (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol Off J Am Soc Clin Oncol 24:1868–1876

    Article  Google Scholar 

  4. Boustead G, Edwards SJ (2007) Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU Int 99:1383–1389

    Article  Google Scholar 

  5. Sweeney CJ et al (2015) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737–746

    Article  CAS  Google Scholar 

  6. James ND et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet Lond Engl 387:1163–1177

    Article  CAS  Google Scholar 

  7. Gravis G et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14:149–158

    Article  CAS  Google Scholar 

  8. Fizazi K et al (2017) Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 377:352–360

    Article  CAS  Google Scholar 

  9. James ND et al (2017) Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 377:338–351

    Article  CAS  Google Scholar 

  10. Ryan CJ et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16:152–160

    Article  CAS  Google Scholar 

  11. Ryan CJ et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148

    Article  CAS  Google Scholar 

  12. Beer TM et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433

    Article  Google Scholar 

  13. Tannock IF et al (2004) Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med 351:1502–1512

    Article  CAS  Google Scholar 

  14. Droz J-P et al (2010) Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol. 73:68–91

    Article  Google Scholar 

  15. Kellokumpu-Lehtinen P-L et al (2013) 2‑Weekly versus 3‑weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 14:117–124

    Article  CAS  Google Scholar 

  16. Parker CC et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet Lond Engl 392:2353–2366

    Article  Google Scholar 

  17. Heidenreich A et al (2013) Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol. 63:977–982

    Article  CAS  Google Scholar 

  18. Eisenberger M et al (2017) Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol Off J Am Soc Clin Oncol. 35:3198–3206

    Article  CAS  Google Scholar 

  19. Calopedos RJS, Chalasani V, Asher R, Emmett L, Woo HH (2017) Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20:352–360

    Article  CAS  Google Scholar 

  20. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E (2003) A systematic overview of radiation therapy effects in skeletal metastases. Swed, Bd. 42. Acta, Oncol. Stockh, S 620–633

    Google Scholar 

  21. Hussain M et al (2018) Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 378:2465–2474

    Article  CAS  Google Scholar 

  22. Davis ID et al (2019) Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 381:121–131

    Article  CAS  Google Scholar 

  23. Smith MR et al (2018) Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 378:1408–1418

    Article  CAS  Google Scholar 

  24. Chi KN et al (2019) Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 381:13–24

    Article  CAS  Google Scholar 

  25. von der Maase H et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol Off J Am Soc Clin Oncol. 23:4602–4608

    Article  Google Scholar 

  26. Galsky MD et al (2012) Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 23:406–410

    Article  CAS  Google Scholar 

  27. Leitlinienprogramm Onkologie: Harnblasenkarzinom. https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/. Zugegriffen: Märch 2020

  28. Balar AV et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl 389:67–76

    Article  CAS  Google Scholar 

  29. IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) | Elsevier Enhanced Reader. https://reader.elsevier.com/reader/sd/pii/S0923753419604072?token=C4E5C84E0EBF2A42A6176407C086DC5534D457D4DA516270C1D93F3B924EBE76F9A60AAE3B6458164FAAD079BDFD05CA https://doi.org/10.1093/annonc/mdz394.047. Zugegriffen: März 2020

  30. Balar AV et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18:1483–1492

    Article  CAS  Google Scholar 

  31. Bellmunt J et al (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 376:1015–1026

    Article  CAS  Google Scholar 

  32. Sharma P et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 18:312–322

    Article  CAS  Google Scholar 

  33. Bellmunt J et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol Off J Am Soc Clin Oncol. 27:4454–4461

    Article  CAS  Google Scholar 

  34. Bellmunt J et al (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 24:1466–1472

    Article  CAS  Google Scholar 

  35. Leitlinienprogramm Onkologie: Nierenzellkarzinom. https://www.leitlinienprogramm-onkologie.de/leitlinien/nierenzellkarzinom/. Zugegriffen: März 2020

Download references

Author information

Authors and Affiliations

  1. Praxiskliniken Urologie Rhein Ruhr, Schulstr. 11, 45468, Mülheim an der Ruhr, Deutschland

    A. Eisenhardt

  2. Klinik und Poliklinik für Urologie, Kinderurologie und Uroonkologie, Universitätsklinikum Essen, Essen, Deutschland

    A. Eisenhardt

  3. Klinik für Urologie, Malteser Krankenhaus Seliger Gerhard Bonn, Bonn, Deutschland

    C.-H. Ohlmann

  4. Urologikum Lübeck, Lübeck, Deutschland

    C. Doehn

  5. Deutsche Uro-Onkologen (d-uo), Berlin, Deutschland

    C. Doehn

Authors
  1. A. Eisenhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C.-H. Ohlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Doehn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Eisenhardt.

Ethics declarations

Interessenkonflikt

A. Eisenhardt ist Berater/Referent für Ipsen Pharma, Apogepha, Medac, Janssen Cilag, Takeda. C. Ohlmann ist Berater/Referent für Bayer, Sanofi, Janssen, BMS, MSD. C. Doehn ist Berater/Referent für BMS, Eisai, EUSA Pharm, Ipsen, MSD, Merck Serono, Novartis, Pfizer, Roche.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eisenhardt, A., Ohlmann, CH. & Doehn, C. Algorithmen zur Systemtherapie bei Prostata‑, Urothel- und Nierenzellkarzinom. Urologe 59, 533–543 (2020). https://doi.org/10.1007/s00120-020-01182-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-020-01182-0

Schlüsselwörter

Keywords

Search

Navigation